MeSH tree: C17.800.815.193
One of the first signs of puberty is likely to be new body odor. This is perfectly normal. Every child will have some body odor as puberty begins. This often starts as early as age 8 or 9.
Oct 13, 2025
0
34
The U.S. Food and Drug Administration has approved the supplemental new drug application for Zoryve (roflumilast) cream 0.05% for the topical treatment of mild-to-moderate atopic dermatitis in children 2 to 5 years of age.
Oct 9, 2025
0
15
A few easy-to-implement tools—a training video, electronic health record prompts and handouts for families—greatly increased how often pediatricians recommended early peanut introduction to infants, reports a new clinical ...
Oct 6, 2025
0
17
The U.S. Food and Drug Administration has approved Opzelura cream 1.5% (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD).
Sep 29, 2025
0
11
A new international study presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025 reveals that adults with atopic eczema (AE) are significantly more likely to experience suicidal thoughts, with ...
Sep 16, 2025
0
14
Maternal stress during pregnancy may be partly to blame for childhood eczema, according to a study on mice published in the journal Nature.
Eczema and psoriasis are common skin conditions, and they can both appear as rashes that may itch or burn. If you get rashes often, you might wonder if you have one or the other. In fact, you could have both eczema and psoriasis ...
Aug 26, 2025
0
15
For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study published online July 15 in the American Journal of Clinical Dermatology.
Aug 13, 2025
0
17
In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented. The focused update was published online in the Journal of the American Academy of Dermatology.
Jul 28, 2025
0
64
Oregon Health & Science University-led research is reporting that daily full-body emollient use starting before 9 weeks of age lowered atopic dermatitis incidence by 24 months in a representative US infant cohort.
